
Findings are based on a meta-analysis of 51 studies and 739 pregnancies.
Findings are based on a meta-analysis of 51 studies and 739 pregnancies.
Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Childhood myopia progression could be treated with low-dose atropine due to the safety and efficacy displayed in this study.
A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged the limitations and current challenges with these data.
The Supreme Court protected Medicaid recipients’ right to sue nursing homes; wildfire smoke raises the risk of contracting COVID-19; CMS announced a new value-based primary care model.
Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, discussed the importance of germline genetic testing in patients with triple-negative breast cancer and other cancer types.
Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse overall survival in prostate cancer without distant metastasis based on conventional imaging.
If payers can agree on consensus criteria to improve care quality or costs, that will help physicians remember and try to be compliant, said Samyukta Mullangi, MD, MBA, incoming medical director at Thyme Care.
The use of immune therapies for hematological malignancies is expanding beyond chimeric antigen receptor (CAR) T-cell therapies in the traditional lymphoid disease states, but the impact on patient quality of life must remain top of mind, according to speakers at the European Hematology Association 2023 Congress.
The Revolutionizing Atopic Dermatitis (RAD) meeting took place April 29 through May 1 in Washington, DC, with The American Journal of Managed Care® there to cover the meeting. Some of the top news you may have missed is right below.
Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis.
The plan aims to reverse a significant surge in sexually transmitted infections, including gonorrhea, syphilis, and chlamydia.
Watch and see what Michael Shapiro, DO, FASPC, president-elect of the American Society for Preventive Cardiology, wants you to know about this year's ASPC Congress on CVD Prevention.
The pilot 4T study showed consistent hemoglobin A1C improvement in all children with type 1 diabetes (T1D) after 1 year, underscoring the importance of early continuous glucose monitoring (CGM) following diagnosis, explained David Maahs, MD, PhD, professor of pediatrics at Stanford University and division chief of pediatric endocrinology at Lucile Packard Children’s Hospital.
Children with narcolepsy often have disrupted nighttime sleep (DNS), which could lead to other effects, such as memory issues.
In this interview with The American Journal of Managed Care®, Symielle A. Gaston, PhD, MPH, of the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health, explores the relationship between sleep health and outcomes disparities among patients of various races and ethnicities.
The possibility of individual Americans receiving a health insurance rebate is slim; more states are legalizing fentanyl test strips to fight soaring opioid deaths; reanimated hearts donated after death work just as well for transplants, study finds.
Patients with depression, anxiety, or both at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) have worse overall survival and lymphoma-specific survival.
The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
The phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end point.
Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.
Researchers assessed overall survival outcomes in patients in France.
Out of multiple risk factors, African American and Hispanic individuals with Medicaid are at a significantly higher risk of uncontrolled asthma.
The Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Symptoms Scale demonstrated logical patterns of upper and lower respiratory symptoms among participants.
Posters presented at the SLEEP 2023 conference showed that transition between medications was easy but 1 medication felt more effective to patients.
Targeting insomnia with cognitive behavior therapy is almost like a frontline therapy, because by doing so, you’re able to improve a whole host of other symptoms that would coexist with insomnia, explained Sheila Garland, PhD, MSc, Memorial University in Newfoundland, Canada.
In a review of adults with type 1 diabetes (T1D), having a body mass index (BMI) <18.5 kg/m2 increased the risk of all-cause mortality by 3.4 times compared with normal BMI.
New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.
A panel at SLEEP 2023 discussed the ways that long COVID-19 has affected numerous areas of sleep health.
According to a spokesperson, Merck is prepared to take the lawsuit to the Supreme Court as it challenges drug price negotiations as part of the Inflation Reduction Act.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.